Wechselwirkungen · Etcamah
Etcamah 75 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-153192 · Präparat HOS-100955
CYP3A4/5 inducers The exposure to camizestrant is expected to decrease if co-administered with moderate and strong CYP3A4/5 inducers. Clinically, a single 75 mg camizestrant dose co-administered orally with repeat doses of carbamazepine, a strong CYP3A4/5 inducer, resulted in camizestrant geometric mean ratios for Cmax and AUC of 0.41 [90% CI: 0.37,0.46] and 0.29 [90% CI: 0.28,0.32], respectively. The co- administration of camizestrant and a strong CYP3A4/5 inducer (including but not limited to: carbamazepine, phenytoin, rifampicin and St John’s Wort) should be avoided. An alternative medicinal product with no or weak potential to induce CYP3A4/5 should be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): carbamazepine (HOS-085618) camizestrant (HOS-153187) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T14:07:16Z · SHA-256 b50ea6ed7223cee8c2b96a46475d89e0843fb8c57083f80f60c2957e00e303a8 · Passage 1f799bf98873cd61f12df4b9094aad689f16af2342508289321ed54f160a6861 · Zeichen 321–997 im Abschnitt